Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Summary

This study is being conducted to compare the efficacy and safety of exemestane alone or in combination with pazopanib in postmenopausal women who have hormone receptor positive breast cancer and have failed therapy with tamoxifen, anastrazole or letrozole.

Timeline

Start

2008-04

Primary completion

2012-11

Completion

2012-11

Outcome

Outcome not reported

Stopped (Enrollment): “Cancelled Before Enrollment”

Drugs

Indications